Selexis SA has signed two service agreements that provide OSE Immunotherapeutics (www.ose-immuno.com/en) with access to high performance research cell banks (RCBs) from the Selexis’ SUREtechnology Platform. The agreements are designed to help OSE Immunotherapeutics advance two of its preclinical products based on immune activation and regulation. Effi-DEM is a new-generation checkpoint inhibitor that blocks the Signal Regulatory Protein-α (SIRP-alpha) receptor expressed by myeloid suppressor ...